ArthNow Logo
ArthNow
•3 min read•
✦Reported by Reuters

Indian billionaire, doctors spar over $900 brain blood-flow tracker Temple

Indian billionaire, doctors spar over $900 brain blood-flow tracker Temple
Source: Reuters

Executive Brief • Key Highlights

Fast factual intelligence distilled for busy investors, executives, and answer bots:

  • ✓Indian billionaire Deepinder Goyal faces criticism from doctors over his $900 wearable device, Temple.
  • ✓While sportspersons like Shubman Gill use it, experts say its claims about tracking brain blood flow lack peer-reviewed research.
  • ✓Doctors called the device a gimmick, but Goyal said it is just a fitness and wellness tracker.

Story at a Glance

Category
Indian Markets
Reported By
Reuters
Reading Speed
3 Minute(s)
Market Focus
India Economy

MUMBAI, Nov 11 (Reuters) - A tiny, $900 wearable device being developed by an Indian billionaire entrepreneur and showcased by some of ​the country's top sportspersons has sparked criticism from doctors who say its claims of tracking blood flow to the ‌brain are exaggerated.

The Temple device is less than 1 inch (2.54 cm) wide and weighs under 2 grams (0.07 oz). It sticks to the side of the head between the forehead and the ear, or the temple area.

Sign up here.

Promotional materials for the device, developed by Deepinder Goyal, say that its BrainFlow feature shows how well the brain ​is being supplied with blood in real time and its Entropy feature can detect how hard the body works to shed ​heat.

🔒
Premium Content

Unlock the Full Story with ArthNow Premium

To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.

✓ Full Unabridged Reports✓ Executive Audio Briefs✓ 100% Ad-Free Reading
Verified Publication Source

Reuters

Read the full, original unfiltered story directly on the publisher's portal.

Visit Original Article

This brief is for information only and is not investment advice. ArthNow is not a SEBI-registered investment adviser and does not publish buy or sell recommendations. Original reporting is credited to the publisher named above. Read our editorial policy or report an error.